Prometheus Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: San Diego CA United States (1995)
Status: Acquired by Merck (2023)

Organization Overview

First Clinical Trial
2005
NCT00113503
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Prometheus Biosciences | Prometheus Biosciences, Inc. | Prometheus Inc. | Prometheus Laboratories | Prometheus Labs | Prometheus Therapeutics and Diagnostics | Prometheus USA, Ltd. Co.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Biliary Atresia (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Adenosquamous (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Renal Cell (Phase 2)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 2)

Diarrhea (Phase 4)

Graft vs Host Disease (Phase 2)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 1)

Melanoma (Phase 4)

Skin Neoplasms (Phase 2)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial APIs: 24